Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of the Effects of Buprenophine as Add-on Treatment to Antidepressants in Treating Acutely Suicidal Depressed Inpatients

NCT00863291 is registered in ClinicalTrials.gov with Abarbanel Mental Health Center as lead sponsor.

NCT NCT00863291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00863291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of the Effects of Buprenophine as Add-on Treatment to Antidepressants in Treating Acutely Suicidal Depressed Inpatients
Lead sponsor
Abarbanel Mental Health Center
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2007
Completion date
November 30, 2008
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, suicidal action, suicidal ideation